PositoAI
a positivity index
Home Explore Actions Flows Indices News Watchlist Compare PosiDemy Screeners Insights

PosiRed · Red Flags

Every red flag PositoAI has recorded across all tracked companies: regulator orders, bankruptcy filings and stock-exchange delisting notices. Stress signals such as promoter pledges and late filings are listed under Yellow Flags (PosiYellow). Each red flag lowers the company's Positivity Score until it is resolved. How PosiFlag works →

Newest First Most Severe First
6 KALA BIO, Inc.KALA 23 Jan 2026

Stock exchange listing-rule deficiency notice (8-K Item 3.01)

The company reported in a Form 8-K (Item 3.01) filed on 23 Jan 2026 that its stock exchange notified it of not meeting a continued-listing rule. Continued non-compliance can lead to delisting.

6 Aprea Therapeutics, Inc.APRE 23 Jan 2026

Stock exchange listing-rule deficiency notice (8-K Item 3.01)

The company reported in a Form 8-K (Item 3.01) filed on 23 Jan 2026 that its stock exchange notified it of not meeting a continued-listing rule. Continued non-compliance can lead to delisting.

6 Nexalin Technology, Inc.NXL 23 Jan 2026

Stock exchange listing-rule deficiency notice (8-K Item 3.01)

The company reported in a Form 8-K (Item 3.01) filed on 23 Jan 2026 that its stock exchange notified it of not meeting a continued-listing rule. Continued non-compliance can lead to delisting.

6 BT Brands, Inc.BTBD 20 Jan 2026

Stock exchange listing-rule deficiency notice (8-K Item 3.01)

The company reported in a Form 8-K (Item 3.01) filed on 20 Jan 2026 that its stock exchange notified it of not meeting a continued-listing rule. Continued non-compliance can lead to delisting.

6 Azio AI Holdings, Inc.AZIO 20 Jan 2026

Stock exchange listing-rule deficiency notice (8-K Item 3.01)

The company reported in a Form 8-K (Item 3.01) filed on 20 Jan 2026 that its stock exchange notified it of not meeting a continued-listing rule. Continued non-compliance can lead to delisting.

6 GRI Bio, Inc.GRI 16 Jan 2026

Stock exchange listing-rule deficiency notice (8-K Item 3.01)

The company reported in a Form 8-K (Item 3.01) filed on 16 Jan 2026 that its stock exchange notified it of not meeting a continued-listing rule. Continued non-compliance can lead to delisting.

6 MicroVision, Inc.MVIS 16 Jan 2026

Stock exchange listing-rule deficiency notice (8-K Item 3.01)

The company reported in a Form 8-K (Item 3.01) filed on 16 Jan 2026 that its stock exchange notified it of not meeting a continued-listing rule. Continued non-compliance can lead to delisting.

6 Autonomix Medical, Inc.AMIX 16 Jan 2026

Stock exchange listing-rule deficiency notice (8-K Item 3.01)

The company reported in a Form 8-K (Item 3.01) filed on 16 Jan 2026 that its stock exchange notified it of not meeting a continued-listing rule. Continued non-compliance can lead to delisting.

6 Alpha Modus Holdings, Inc.AMOD 16 Jan 2026

Stock exchange listing-rule deficiency notice (8-K Item 3.01)

The company reported in a Form 8-K (Item 3.01) filed on 16 Jan 2026 that its stock exchange notified it of not meeting a continued-listing rule. Continued non-compliance can lead to delisting.

6 Z Squared Inc.ZSQR 16 Jan 2026

Stock exchange listing-rule deficiency notice (8-K Item 3.01)

The company reported in a Form 8-K (Item 3.01) filed on 16 Jan 2026 that its stock exchange notified it of not meeting a continued-listing rule. Continued non-compliance can lead to delisting.

6 American Resources CorporationAREC 16 Jan 2026

Stock exchange listing-rule deficiency notice (8-K Item 3.01)

The company reported in a Form 8-K (Item 3.01) filed on 16 Jan 2026 that its stock exchange notified it of not meeting a continued-listing rule. Continued non-compliance can lead to delisting.

6 Artelo Biosciences, Inc.ARTL 16 Jan 2026

Stock exchange listing-rule deficiency notice (8-K Item 3.01)

The company reported in a Form 8-K (Item 3.01) filed on 16 Jan 2026 that its stock exchange notified it of not meeting a continued-listing rule. Continued non-compliance can lead to delisting.

6 NRx Pharmaceuticals, Inc.NRXP 16 Jan 2026

Stock exchange listing-rule deficiency notice (8-K Item 3.01)

The company reported in a Form 8-K (Item 3.01) filed on 16 Jan 2026 that its stock exchange notified it of not meeting a continued-listing rule. Continued non-compliance can lead to delisting.

6 Femasys Inc.FEMY 15 Jan 2026

Stock exchange listing-rule deficiency notice (8-K Item 3.01)

The company reported in a Form 8-K (Item 3.01) filed on 15 Jan 2026 that its stock exchange notified it of not meeting a continued-listing rule. Continued non-compliance can lead to delisting.

6 STAAR Surgical CompanySTAA 15 Jan 2026

Stock exchange listing-rule deficiency notice (8-K Item 3.01)

The company reported in a Form 8-K (Item 3.01) filed on 15 Jan 2026 that its stock exchange notified it of not meeting a continued-listing rule. Continued non-compliance can lead to delisting.

6 Canton Strategic Holdings, Inc.CNTN 15 Jan 2026

Stock exchange listing-rule deficiency notice (8-K Item 3.01)

The company reported in a Form 8-K (Item 3.01) filed on 15 Jan 2026 that its stock exchange notified it of not meeting a continued-listing rule. Continued non-compliance can lead to delisting.

6 Serina Therapeutics, Inc.SER 15 Jan 2026

Stock exchange listing-rule deficiency notice (8-K Item 3.01)

The company reported in a Form 8-K (Item 3.01) filed on 15 Jan 2026 that its stock exchange notified it of not meeting a continued-listing rule. Continued non-compliance can lead to delisting.

6 Estrella Immunopharma, Inc.ESLA 13 Jan 2026

Stock exchange listing-rule deficiency notice (8-K Item 3.01)

The company reported in a Form 8-K (Item 3.01) filed on 13 Jan 2026 that its stock exchange notified it of not meeting a continued-listing rule. Continued non-compliance can lead to delisting.

6 Co-Diagnostics, Inc.CODX 13 Jan 2026

Stock exchange listing-rule deficiency notice (8-K Item 3.01)

The company reported in a Form 8-K (Item 3.01) filed on 13 Jan 2026 that its stock exchange notified it of not meeting a continued-listing rule. Continued non-compliance can lead to delisting.

6 Telomir Pharmaceuticals, Inc.TELO 12 Jan 2026

Stock exchange listing-rule deficiency notice (8-K Item 3.01)

The company reported in a Form 8-K (Item 3.01) filed on 12 Jan 2026 that its stock exchange notified it of not meeting a continued-listing rule. Continued non-compliance can lead to delisting.

← Page 40 of 46 →

Disclaimer — PositoAI is a research and screening tool for educational and informational purposes. It is not investment advice or a recommendation to buy or sell any security or mutual fund. Scores and rankings are calculated by PositoAI's own method using publicly available data, which may be incomplete, delayed or inaccurate, and past performance does not indicate future results. AI summaries of company news may contain errors. PositoAI is not registered with the SEC, SEBI or any other regulatory authority. Please do your own research or consult a licensed financial advisor before investing.